NewAmsterdam Pharma granted 40,000 share options to two new hires as part of its inducement plan.
Quiver AI Summary
NewAmsterdam Pharma Company N.V., a biopharmaceutical firm focused on developing oral, non-statin medications for patients at risk of cardiovascular disease due to high LDL cholesterol, announced the approval of inducement share options for 40,000 ordinary shares to two new non-executive hires. These options, granted under the 2024 Inducement Plan, have an exercise price of $39.61 per share based on the closing market price on December 1, 2025. The options will vest over four years, with 25% becoming available after one year and the remainder vesting in monthly installments. NewAmsterdam is also conducting phase 3 studies on its LDL-lowering therapy, obicetrapib, to address unmet needs in safe and effective cholesterol management.
Potential Positives
- Approval of inducement share options for new hires demonstrates NewAmsterdam's commitment to attracting top talent, which can enhance the company's capabilities and support its growth strategy.
- The share options, tied to the company's performance, align the interests of new employees with those of shareholders, potentially driving higher levels of engagement and productivity.
- The company's focus on developing innovative therapies for cardiovascular disease addresses a significant unmet medical need, highlighting its potential for impact in the healthcare market.
Potential Negatives
- The announcement of inducement share options for new hires may indicate challenges in attracting talent, suggesting a potential struggle for the company to entice candidates without significant financial incentives.
- The need to grant inducement options might reflect underlying issues such as company instability or difficulties in maintaining competitive compensation packages.
- The vesting schedule tied to continued service may raise concerns about employee retention and long-term commitment to the company.
FAQ
What inducement share options did NewAmsterdam Pharma grant?
NewAmsterdam Pharma granted inducement share options covering 40,000 ordinary shares to two non-executive new hires.
What is the exercise price for the new share options?
The exercise price for the new share options is $39.61, based on the market price on December 1, 2025.
How will the share options vest?
The share options will vest over four years, with 25% vesting after one year and the rest in monthly installments.
What is the purpose of the 2024 Inducement Plan?
The 2024 Inducement Plan is designed to incentivize new employees to accept job offers at NewAmsterdam Pharma.
What is NewAmsterdam Pharma's mission?
NewAmsterdam Pharma aims to improve patient care for those with metabolic diseases lacking effective therapies for lowering LDL cholesterol.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NAMS Insider Trading Activity
$NAMS insiders have traded $NAMS stock on the open market 18 times in the past 6 months. Of those trades, 6 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $NAMS stock by insiders over the last 6 months:
- LOUISE FREDERIKA KOOIJ (Chief Accounting Officer) has made 0 purchases and 4 sales selling 176,342 shares for an estimated $4,533,035.
- DOUGLAS F KLING (Chief Operating Officer) has made 0 purchases and 5 sales selling 198,612 shares for an estimated $4,025,796.
- JOHANNES JACOB PIETER KASTELEIN (Chief Scientific Officer) has made 0 purchases and 3 sales selling 100,000 shares for an estimated $2,471,639.
- JAMES N TOPPER has made 6 purchases buying 14,755 shares for an estimated $295,267 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NAMS Hedge Fund Activity
We have seen 68 institutional investors add shares of $NAMS stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 3,630,743 shares (+190.6%) to their portfolio in Q3 2025, for an estimated $103,258,330
- CAPITAL WORLD INVESTORS added 1,434,986 shares (+17.1%) to their portfolio in Q3 2025, for an estimated $40,811,001
- FCPM III SERVICES B.V. removed 1,419,729 shares (-13.4%) from their portfolio in Q3 2025, for an estimated $40,377,092
- JENNISON ASSOCIATES LLC added 1,252,451 shares (+42.5%) to their portfolio in Q3 2025, for an estimated $35,619,706
- DUQUESNE FAMILY OFFICE LLC added 1,091,525 shares (+131.2%) to their portfolio in Q3 2025, for an estimated $31,042,971
- MORGAN STANLEY added 859,772 shares (+134.8%) to their portfolio in Q3 2025, for an estimated $24,451,915
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 849,260 shares (-16.6%) from their portfolio in Q3 2025, for an estimated $24,152,954
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NAMS Analyst Ratings
Wall Street analysts have issued reports on $NAMS in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 11/06/2025
- Citigroup issued a "Buy" rating on 06/17/2025
- Needham issued a "Buy" rating on 06/12/2025
- Stifel issued a "Buy" rating on 06/10/2025
To track analyst ratings and price targets for $NAMS, check out Quiver Quantitative's $NAMS forecast page.
$NAMS Price Targets
Multiple analysts have issued price targets for $NAMS recently. We have seen 7 analysts offer price targets for $NAMS in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Asad Haider from Goldman Sachs set a target price of $37.0 on 12/02/2025
- Leonid Timashev from RBC Capital set a target price of $44.0 on 11/06/2025
- Serge Belanger from Needham set a target price of $46.0 on 11/05/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $52.0 on 10/20/2025
- Geoff Meacham from Citigroup set a target price of $50.0 on 10/17/2025
- Yanan Zhu from Wells Fargo set a target price of $45.0 on 08/25/2025
- James Condulis from Stifel set a target price of $44.0 on 06/10/2025
Full Release
NAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 40,000 of NewAmsterdam’s ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to $39.61, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on December 1, 2025, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
[email protected]
